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Summary
Compared with the general population, women who
have inherited a germline mutation in the BRCA1 gene
have a greatly increased risk of developing breast cancer.
However, there is also substantial interindividual vari-
ability in the occurrence of breast cancer among BRCA1
mutation carriers. We hypothesize that other genes, par-
ticularly those involved in endocrine signaling, may
modify the BRCA1-associated age-specific breast cancer
risk. We studied the effect of the CAG repeat-length
polymorphism found in exon 1 of the androgen-receptor
(AR) gene (AR-CAG). AR alleles containing longer CAG
repeat lengths are associated with a decreased ability to
activate androgen-responsive genes. Using a sample of
women who inherited germline BRCA1 mutations, we
compared AR-CAG repeat length in 165 women with
and 139 women without breast cancer. We found that
women were at significantly increased risk of breast can-
cer if they carried at least one AR allele with 28 CAG
repeats. Women who carried an AR-CAG allele of 28,
29, or 30 repeats were given a diagnosis 0.8, 1.8, or
6.3 years earlier than women who did not carry at least
one such allele. All 11 women in our sample who carried
at least one AR-CAG allele with 29 repeats had breast
cancer. Our results support the hypothesis that age at
breast cancer diagnosis is earlier among BRCA1 muta-
tion carriers who carry very long AR-CAG repeats.
These results suggest that pathways involving androgen
signaling may affect the risk of BRCA1-associated breast
cancer.
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Introduction
Inheritance of a germline mutation in the BRCA1 gene
(MIM 113705) is associated with an increased risk of
developing breast cancer. However, there is also sub-
stantial variability in the ages at which breast cancers
are diagnosed in BRCA1 mutation carriers (Easton et
al. 1995; Narod et al. 1995; Rebbeck 1999). These ob-
servations imply that germline mutations inBRCA1may
be necessary to explain the Mendelian pattern of cancer
in some families but may not be sufficient to completely
describe the interindividual variability in the age-specific
risk of cancer. The ability to effectively apply risk-pre-
diction or cancer-prevention strategies in BRCA1 car-
riers may therefore depend on knowledge of risk-mod-
ifying factors in addition to BRCA1 mutation status.
Steroid hormone pathways regulate BRCA1 expres-
sion (Gudas et al. 1995; Marks et al. 1997). Therefore,
we hypothesize that allelic variation in genes governing
hormonal signaling known to play a role in normal de-
velopment and cancer risk may be involved in modifi-
cation of BRCA1-associated cancer risk. For example,
the androgen-receptor gene AR (MIM 313700), which
functions as a ligand-dependent transcriptional activator
in response to androgens, contains a highly polymorphic
CAG trinucleotide repeat (AR-CAG) encoding gluta-
mines in its first exon. The length of the AR-CAG poly-
morphism is inversely associated with the degree of tran-
scriptional activation by the AR (Chamberlain et al.
1994; Kazemi-Esfarjani et al. 1995). Individuals with X-
linked spinal and bulbar muscular atrophy (SBMA, Ken-
nedy disease) have 40 or more AR-CAG repeats and
manifest clinical androgen insensitivity (LaSpada et al.
1991). AR mediates breast tumor growth and progres-
sion (Zhu et al. 1997; Birrell et al. 1998). Increased AR-
CAG repeat length has also been associated with de-
creased prostate cancer risk, presumably because of a
decreased ability of androgens to stimulate transcription
of genes involved in prostate growth (Hardy et al. 1996;
Giovannucci et al. 1997; Ingles et al. 1997). However,
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this result has not been replicated in all populations (Ee-
les et al. 1998). These findings suggest that AR-CAG
repeat-length polymorphism may be involved in modi-
fying the development of diseases caused by alterations
in endocrine signaling.
Subjects and Methods
Subjects
A sample of 304 women who carry disease-associated
germline BRCA1 mutations was ascertained through
families with a history of breast and/or ovarian cancer
at Creighton University, the Dana Farber Cancer Insti-
tute, The University of Michigan, Fox Chase Cancer
Center, The University of Pennsylvania, The University
of Utah, and Women’s College Hospital (Toronto) be-
tween 1978 and 1997. Women were self- or physician-
referred because of a strong family history of breast and/
or ovarian cancer. These women provided written in-
formed consent for research under protocols approved
by the institutional review boards at each institution. Of
these 304 women, 165 (54%) were affected (mean age
40.5 years, range 21–73 years) and 139 (46%) were
unaffected by breast cancer (mean age 44.5 years, range
19–89 years).
Genotype Analysis
All study participants provided peripheral blood sam-
ples from which genomic DNA was extracted according
to standard protocols. We used PCR to amplify the AR-
CAG trinucleotide repeat found in exon 1 of AR, as
described elsewhere (Giovannucci et al. 1997). The AR-
CAG repeat-length polymorphism was modeled in three
ways to reflect two alternative hypotheses about the ac-
tivity of AR in breast carcinogenesis. The first two mod-
els reflect the activity of specific alleles acting at the level
of the breast epithelial cell to modulate androgen sig-
naling. First, the shorter of the two repeat-length alleles
for each subject was considered in a survival analysis
model. For example, if an individual inherited alleles
with 22 and 25 AR-CAG repeats, we considered the
effect of the 22-repeat allele on breast cancer penetrance.
This allowed us to evaluate whether having at least one
short-repeat allele affected breast cancer penetrance. Sec-
ond, the longer of the two repeat-length alleles for each
subject was considered in the survival model. As before,
this allowed us to evaluate whether having at least one
very long allele affected breast cancer penetrance. The
third model reflects the effect of the combined AR ge-
notype as having endocrine or paracrine activity on lev-
els of steroid hormones in breast carcinogenesis. This
hypothesis was modeled by consideration of the mean
allele repeat length as a measure of jointly considering
both alleles in each individual.
Statistical Methods
Cox proportional hazards models were used to eval-
uate the difference in breast cancer penetrance across
AR-CAG repeat lengths. To correct for nonindepend-
ence of observations among participants drawn from the
same families, the robust variance-covariance estimation
approach of Lin and Wei (1989) was used, as imple-
mented in STATA (StataCorp., release 5). Participants
were followed up (retrospectively) from birth until one
of several events occurred. The primary event of interest
was the first diagnosis of a primary invasive breast can-
cer ( 54%). Participants with no prior breastn  165
cancer diagnosis were censored when they developed
ovarian cancer ( ; 13%), had a prophylactic mas-n  40
tectomy or oophorectomy ( ; 15%) or died (n  46 n 
; 5%)—or when none of these events had occurred15
by the end of the observation period ( ; 13%). Alln  38
Cox proportional hazards analyses were undertaken
with and without adjustment for three hormone-related
risk factors: age at menarche, age at first live birth, and
total number of full-term pregnancies (parity). Parity
and age at menarche are the only factors on this list that
have been previously suggested as modifiers of breast
cancer risk in BRCA1 carriers (Narod et al. 1995).
AR-CAG repeat length is known to be correlated with
endocrine signaling. However, the AR-CAG repeat is
continuously distributed, and there is no a priori point
at which cutoffs may be applied to identify allele-specific
risk groups. Therefore, sensitivity analyses were under-
taken to compare AR-CAG genotype classes by use of
the log rank statistic estimated from Kaplan-Meier mod-
els. Risk (hazard) ratios were estimated by using Cox
proportional hazards models. These analyses involved
dichotomizing the total sample by using cutpoints along
the AR-CAG repeat-length distribution to compare
women whose AR-CAG repeat allele was less than,
greater than, or equal to the specified number of repeats.
Cutpoints were made within the range of observed AR-
CAG repeat lengths. First, the effect of having at least
one very short allele was evaluated by comparing groups
divided at repeat lengths !15/15 through !25/25,
where the repeat-length cutpoint was determined by the
shorter of a woman’s two AR alleles. Analyses were
undertaken in this range because few alleles with !14
AR-CAG repeats were observed. The 25-repeat allele
was used as the upper cutpoint bound, because few
shorter alleles with 125 repeats were observed. Second,
the effect of having at least one very long allele was
evaluated by comparison of groups divided at allele
lengths !20/20 through !30/30, where the repeat-
length cutpoint was determined by the longer of a
woman’s two AR alleles. The 30-repeat AR-CAG allele
was used as the upper bound, because few 31- or 32-
repeat alleles were observed in this sample (fig. 1). This
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Figure 1 AR-CAG repeat-length distribution by breast cancer status
analysis allowed us to identify critical cutpoints along
the continuous allele distribution for which breast cancer
penetrance may be modified.
Results
We evaluated the effect of AR-CAG repeat length on
breast-cancer penetrance in 304 womenwho carry germ-
line mutations in the BRCA1 gene.Mutations inBRCA1
spanned the majority of the gene’s coding region (rang-
ing fromMet1Ile to 5439delA). Mutations included 198
(65%) deletions (including large genomic deletions), 55
(18%) nonsense mutations, 31 (10%) insertions, and 20
(7%) disease-associated missense mutations. The three
most commonly identified mutations were 185delAG
( ), Q1313ter ( ), and 5382insC ( ).n  49 n  33 n  26
A frequency histogram depicting the observed distri-
bution of AR-CAG repeat lengths is presented in figure
1. Although the distributions among cancer patients and
cancer-free women are generally similar, we observed a
skew in the distribution of breast cancer cases toward
inheritance of at least one longer-repeat allele compared
with cancer-free women. The median repeat length was
22 (range 8–32). The overall allele repeat distribution
in our sample (including mean, median, and range) is
similar to that of control populations reported elsewhere
(Giovannucci et al. 1997; Hakimi et al. 1997). The me-
dian repeat length of the shorter allele carried by each
individual was 21 (range 8–30). The median repeat
length of the longer allele carried by each individual was
24 (range 17–32).
We found no simple association between breast cancer
penetrance and continuous CAG repeat variables coded
as mean repeat length ( , 95% CI 0.96–1.10),RR  1.03
shorter repeat length ( , 95% CI 0.95–1.07),RR  1.01
or longer repeat length ( , 95%CI 0.98–1.10).RR  1.04
To identify points in the continuous AR-CAG repeat-
length distribution associated with modified breast can-
cer penetrance, we performed sensitivity analyses using
the shorter or longer of a woman’s two alleles. No effect
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Figure 2 HRs associated with shorter AR-CAG repeat length among 304 BRCA1 mutation carriers
of a woman’s shorter AR allele was observed (fig. 2). In
contrast, women who carried at least one long AR-CAG
repeat allele (28 repeats) had a significantly earlier age
at breast cancer diagnosis than women without one
long-repeat allele (fig. 3). In the group of women who
carried at least one allele with28 repeats, we observed
eight breast cancers (mean age at diagnosis 41.0 years)
and four unaffected women (mean age at diagnosis 37.5
years) with 28-repeat alleles, four breast cancers (mean
age at diagnosis 40.8 years) in women with 29-repeat
alleles, and seven breast cancers (mean age at diagnosis
34.0 years) in women with 30-repeat alleles. There
were no women in this study who carried two alleles
with 128 repeats.
Estimates of hazard ratios (HRs) from Cox propor-
tional hazards models indicated an increasing breast can-
cer penetrance as the repeat-length cutpoint increased
(fig. 3). Women with 28 AR-CAG repeats ( )n  19
developed breast cancer 0.8 years earlier than women
who had only shorter alleles ( ; , 95%n  146 HR  1.81
CI 1.06–3.08). Similarly, women with 29 AR-CAG
repeats ( ) developed breast cancer 1.8 years ear-n  11
lier than women who had only shorter alleles (n 
; , 95% CI 1.51–4.69), and women with154 HR  2.66
30 AR-CAG repeats ( ) developed breast cancern  7
6.3 years earlier than women who had only shorter al-
leles ( ; , 95% CI 1.31–15.16). Asn  158 HR  4.45
indicated in figure 1, all women in our sample who car-
ried at least one allele with 29 repeats were affected.
All estimates presented here were made without adjust-
ment for other potential confounding variables. How-
ever, inferences from survival analyses comparing AR-
CAG repeats on breast cancer penetrance were identical
in analyses that were unadjusted and adjusted for parity,
age at menarche, age at first live birth, or ascertainment
site. Note that the 24 individuals who carried at least
one AR-CAG allele of 28 repeats included 20 unre-
lated women and two pairs of relatives (i.e., two relatives
in each of two families, each pair carrying the same
mutation). Five of the unrelated women in this group
carried the same BRCA1 mutation (185delAG).
It was not possible to conduct a complete evaluation
of the effect of BRCA1 mutation type given the extreme
heterogeneity in the type and location of BRCA1 mu-
tations. However, we repeated our analyses including
only women with at least one AR-CAG allele of ≥28
repeats by using a sample of womenwith uniqueBRCA1
mutations. Our inferences were similar to those pre-
sented in figure 3: having at least one allele with 28 or
more AR-CAG repeats ( , 95% CI: 1.6–8.4),HR  3.7
29 or more AR-CAG repeats ( , 95% CI:HR  3.6
1.3–9.8), or 30 or more AR-CAG repeats ( ,HR  4.5
95%CI 1.1–18.1) remained significantly associatedwith
breast cancer risk.
Discussion
We report that AR-CAG allele size is associated with
breast cancer penetrance in BRCA1 mutation carriers.
Although the present association study is primarily hy-
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Figure 3 HRs associated with longer AR-CAG repeat length among 304 BRCA1 mutation carriers
pothesis generating, there is a strong biological rationale
for our findings. It is well known that AR-CAG repeat
length modulates the transactivational activity of AR in
vitro and is inversely associated with androgen sensitiv-
ity (LaSpada et al. 1991; Chamberlain et al. 1994; Ka-
zemi-Esfarjani et al. 1995; Tut et al. 1997). The AR is
expressed in normal breast epithelial cells and in some
breast tumors, and it may be coexpressed with the es-
trogen and progesterone receptors in breast tumors
(Hackenberg and Schulz 1996). Androgens are known
to inhibit the growth of some breast cancer cell lines
(Birrell et al. 1995). Ectopic AR expression leads to the
inhibition of breast tumor–cell proliferation in response
to androgens (Szelei et al. 1997). Although side effects
have limited their use, androgens are effective in the
treatment of women with metastatic breast cancer (Gol-
denberg et al. 1973). This information supports the hy-
pothesis that decreased androgen activity associated
with an increased number of AR-CAG repeats may re-
sult in increased breast cancer risk.
One means by which AR may act in breast tumori-
genesis is by androgen signaling acting on the level of
the mammary epithelial cell. Since AR maps to the X
chromosome, breast epithelial cells in women express
only one of the two AR alleles a woman has inherited.
Thus, each cell is under the influence of only a single
AR allele. Acting on knowledge of AR activity in breast
cell proliferation, we hypothesize that decreased andro-
genic activity in breast cells expressing a very long AR-
CAG repeat allele may result in increased breast epi-
thelial cell proliferation. This increased proliferation
may in turn affect the penetrance of breast cancer in
BRCA1 mutation carriers. In support of this hypothesis,
Elhaji et al. (1997) have reported somatic mutations
leading to a significant lengthening of the AR-CAG re-
peats in breast tumors from postmenopausal women.
Thus, our finding of a relationship between the longer
AR-CAG allele and breast cancer risk in BRCA1 mu-
tation carriers supports a model in which the effect is
mediated at the level of the mammary epithelium in a
cell-autonomous fashion.
An alternative to this hypothesis is an endocrine or
paracrine mechanism for the action of AR in breast tu-
morigenesis. Androgens may modulate BRCA1 risk via
an endocrine mechanism by altering the levels of cir-
culating hormones, such as estradiol, or via a paracrine
mechanism involving effects mediated by the mammary
stroma. For example, a recent epidemiologic study of
the relationship between testosterone and breast cancer
risk reported that decreased serum testosterone levels
may have an indirect effect by influencing the bioavail-
ability of estrogen (Zeleniuch-Jaquotte et al. 1997). Al-
ternatively, androgens might act on the mammary
stroma to indirectly affect the growth of the mammary
epithelium. If either of these indirect mechanisms is me-
diating the effect of the AR polymorphism on BRCA1
risk, the effect would be expected to be the result of the
action of the AR in a number of cells, rather than in a
cell-autonomous fashion, and thus would reflect the ac-
tivity of both AR alleles. We modeled this effect of both
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AR alleles as the average of the signal from the two
alleles, and we found no support for this hypothesis.
However, our ability to reject these hypotheses was lim-
ited, and we cannot rule out the possibility that endo-
crine or paracrine effects of androgens may affect breast
cancer risk in BRCA1 mutation carriers.
One limitation of the present study is that the partic-
ipants carried a variety of BRCA1 mutations, and we
could not evaluate the effect of BRCA1 mutation type
or location on the present results. However, it is unlikely
that the heterogeneity of BRCA1 mutations affected the
inferences of this study. Previous reports suggest that the
location of the BRCA1mutation may, in part, determine
breast versus ovarian cancer risk (Gayther et al. 1995).
The data available from large consortia indicate that no
differences exist in breast cancer risk by mutation lo-
cation or type (D. Easton, personal communication).
The common Ashkenazi Jewish mutations in BRCA1
(i.e., 185delAG and 5382insC) confer approximately the
same lifetime breast cancer risk (Struewing et al. 1997).
In addition, the effect of AR-CAG repeat length among
women who carried at least one longer allele of 28
repeats remained, even after limiting the sample to
women who had unique BRCA1 mutations. This sug-
gests that BRCA1 mutation type did not artificially in-
duce the association of AR-CAG alleles and breast can-
cer risk. Given the extreme heterogeneity of mutations
in BRCA1, it is unlikely that a comprehensive analysis
of the effect of mutation location or type could be done.
Furthermore, because the analyses were not limited to
a particular class of mutations, the present results may
be applicable to the general population of BRCA1 mu-
tation carriers from high-risk families. An additional
limitation is that some individuals in the families studied
here may have been excluded because they had died or
were otherwise unable to participate in this research. As
a result, the present results do not allow us to determine
whether this effect implicates AR as an independent
breast cancer risk factor or as a modifier of BRCA1-
associated breast carcinogenesis.
Our results suggest that female BRCA1 mutation car-
riers who have inherited at least one very long AR-CAG
repeat may be diagnosed with breast cancer at a signif-
icantly earlier age than women who do not carry a very
longAR-CAG repeat. Because the frequency of longAR-
CAG repeats is rare, the AR-CAG repeat polymorphism
may be relevant only to some BRCA1mutation carriers.
However, the large magnitude of effect suggests that the
personal impact on breast cancer risk to women who
carry the very long repeats could be substantial. We con-
clude that the length of the AR-CAG repeat may affect
the timing of breast cancer diagnosis in BRCA1 muta-
tion carriers, possibly through modulation of hormonal
responses of individual mammary epithelial cells. How-
ever, these results are preliminary, and it is premature to
consider knowledge aboutAR-CAG genotype in making
clinical decisions about breast cancer risk, surveillance,
or prevention among BRCA1 mutation carriers.
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